Eculizumab biosimilar (Prestige BioPharma)

依库丽单抗生物类似药

Report date: 2024/01/30 19:01:20

Base Information

Drug NameEculizumab biosimilar (Prestige BioPharma)
Drug Alias NamePBP1603PBP-1603
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A